First Wave BioPharma (First Wave BioPharma) Change In Working Capital : $2.19 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is First Wave BioPharma Change In Working Capital?

First Wave BioPharma's change in working capital for the quarter that ended in Dec. 2023 was $0.50 Mil.

First Wave BioPharma's change in working capital for the fiscal year that ended in Dec. 2023 was $2.19 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

First Wave BioPharma Change In Working Capital Historical Data

The historical data trend for First Wave BioPharma's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

First Wave BioPharma Change In Working Capital Chart

First Wave BioPharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-1.70

14.15

17.10

-10.50

2.19

First Wave BioPharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-3.51	0.84	1.11	-0.26	0.50

First Wave BioPharma Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.19 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

First Wave BioPharma Change In Working Capital Related Terms

Thank you for viewing the detailed overview of First Wave BioPharma's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

First Wave BioPharma (First Wave BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » First Wave BioPharma Inc (NAS:FWBI) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

777 Yamato Road, Suite 502, Boca Raton, FL, USA, 33431

Website

https://www.firstwavebio.com

First Wave BioPharma Inc is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical-stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.

Executives

James Sapirstein	director, officer: President and CEO	1517 SAN JACINTO, HOUSTON TX 77002
Sarah Romano	officer: Chief Financial Officer	271 WAVERLY OAKS ROAD, WALTHAM MA 02452
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
David Andrew Hoffman	director	777 YAMATO ROAD, SUITE 502, BOCA RATON FL 33431
Edward Borkowski	director	1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317
Mary Theresa Coelho	director	52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Alastair Riddell	director	C/OAZURRX BIOPHARMA,INC.760 PARKSIDE AVE, DOWNSTATE BIOTECHNOLOGY INCUBATOR,STE217, BROOKLY NY 11226
Vern Lee Schramm	director	1300 MORRIS PARK AVE., BIOCHEMISTRY DEPT., BRONX NY 10461
Gregory Oakes	director	760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226
James Pennington	officer: CHIEF MEDICAL OFFICER	25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545
Daniel H Schneiderman	officer: CHIEF FINANCIAL OFFICER	760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226
Ross Edmund Burke Jr.	10 percent owner	C/O JDJ FAMILY OFFICE SERVICES, P.O. BOX 962049, BOSTON MA 02196
Johan M. Spoor	director, officer: President and CEO	500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Maged Shenouda	director	305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011
Pelican Partners Llc	10 percent owner	PO BOX 2422, WESTPORT CT 06880